Sevion Therapeutics to Present at 13th Annual BIO Investor Forum

13th Annual BIO Investor Forum

BRIDGEWATER, N.J.--()--Sevion Therapeutics (OTCQB:SVON), a clinical stage company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, announced today that Ronald A. Martell, the Company's Chief Executive Officer, will present at the 13th Annual BIO Investor Forum on Tuesday, October 7 at 2:00 p.m. PT at The Palace Hotel in San Francisco, CA.

About Sevion Therapeutics

Sevion Therapeutics is a clinical stage company building and developing a portfolio of innovative therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company’s product candidates are derived from multiple key proprietary technology platforms: cell-based arrayed antibody discovery, ultralong antibody scaffolds, eIF5A apoptotic regulatory systems, and chimerasome nanocages. Sevion has leveraged these technologies to build a pipeline of innovative product candidates. For more information, please visit SevionTherapeutics.com.

Forward-Looking Statements

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company’s ability to integrate the Fabrus science and operations, including the rebranding of the Company as Sevion Therapeutics; the Company’s ability to continue as a going concern; the Company’s ability to recruit patients for its clinical trial; the ability of the Company to consummate additional financings; the development of the Company’s gene and antibody technology; the approval of the Company’s patent applications; the current uncertainty in the patent landscape surrounding small inhibitory RNA and the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company’s products; the timing and success of the Company’s preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance; and the quotation of the Company’s common stock on an over-the-counter securities market, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contacts

For Sevion Therapeutics
For Investors:
Joel Brooks
Chief Financial Officer
info@seviontherapeutics.com
or
Heather Branham, 908-393-9393
or
Argot Partners
David Pitts, 212-600-1902
sevion@argotpartners.com
or
For Media:
Rachel Hutman, 619-849-5384
Rachel@canalecomm.com

Contacts

For Sevion Therapeutics
For Investors:
Joel Brooks
Chief Financial Officer
info@seviontherapeutics.com
or
Heather Branham, 908-393-9393
or
Argot Partners
David Pitts, 212-600-1902
sevion@argotpartners.com
or
For Media:
Rachel Hutman, 619-849-5384
Rachel@canalecomm.com